F

Fortrea Holdings Inc
NASDAQ:FTRE

Watchlist Manager
Fortrea Holdings Inc
NASDAQ:FTRE
Watchlist
Price: 20.69 USD -0.96%
Market Cap: 1.9B USD
Have any thoughts about
Fortrea Holdings Inc?
Write Note

Fortrea Holdings Inc
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fortrea Holdings Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
F
Fortrea Holdings Inc
NASDAQ:FTRE
Total Current Assets
$1.3B
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Total Current Assets
$23.8B
CAGR 3-Years
-1%
CAGR 5-Years
18%
CAGR 10-Years
15%
Danaher Corp
NYSE:DHR
Total Current Assets
$10.1B
CAGR 3-Years
-2%
CAGR 5-Years
-13%
CAGR 10-Years
0%
Mettler-Toledo International Inc
NYSE:MTD
Total Current Assets
$1.2B
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
3%
Agilent Technologies Inc
NYSE:A
Total Current Assets
$4.3B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
-1%
IQVIA Holdings Inc
NYSE:IQV
Total Current Assets
$5.6B
CAGR 3-Years
7%
CAGR 5-Years
7%
CAGR 10-Years
11%
No Stocks Found

Fortrea Holdings Inc
Glance View

Market Cap
1.9B USD
Industry
Life Sciences Tools & Services

Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 19,000 full-time employees. The company went IPO on 2023-06-16. The firm is a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, patient access solutions and other enabling services. The Company’s segments include Clinical Services and Enabling Services. The Company’s global solutions include Clinical Development, Clinical Pharmacology, Drug Development Consulting Services, Device and Diagnostic Development, and Full and Functional Service Provider Models, among others. Its Clinical Development solutions include Early: Phase I/II a, Late: Phase II b/III, Real-World Evidence and Post-Approval Studies, Decentralized Clinical Trials, Data Analysis and Reporting, Clinical Trial Project Management and Monitoring, and Patient Safety and Pharmacovigilance. By therapeutic or specialty areas, it has scientific expertise in cardiovascular, cell and gene therapies, dermatology, diabetes and endocrinology, hepatology, infectious disease, and others.

FTRE Intrinsic Value
32.14 USD
Undervaluation 36%
Intrinsic Value
Price
F

See Also

What is Fortrea Holdings Inc's Total Current Assets?
Total Current Assets
1.3B USD

Based on the financial report for Dec 31, 2023, Fortrea Holdings Inc's Total Current Assets amounts to 1.3B USD.

What is Fortrea Holdings Inc's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
10%

Over the last year, the Total Current Assets growth was 0%. The average annual Total Current Assets growth rates for Fortrea Holdings Inc have been 10% over the past three years .

Back to Top